3 registrations that name ergothioneine as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 3 registrations
RecruitingNCT06487546
Repletion of Ergothioneine in Patients With Kidney Failure
No phase
Stanford University
About 28 people
Started Apr 1, 2025
In plain words A study of ergothioneine in people 18 and older, run by Stanford University. It plans to enroll about 28 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Esrd.
kidney failure receiving hemodialysis or peritoneal dialysis
The exclusion criteria are on the listing.
What it tests, as registered
Ergothioneine; Placebo
Registered summary
Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.
Where, as registered
1 US site in 1 state.
RecruitingNCT07750002
NVTIA® Ergothioneine for Healthy Aging and Skin Health
No phase
EUROPEAN LIFE SCIENCE RESEARCH ASSOCIATION
About 50 people
Starts Aug 15, 2026 (estimated)
In plain words A study of ergothioneine in people 35 to 55, run by EUROPEAN LIFE SCIENCE RESEARCH ASSOCIATION. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 35 to 55; healthy volunteers accepted. Conditions: Healthy Aging; Skin Aging; Oxidative Stress.
Participants must meet all of the following criteria:
Male or female adults aged 35 to 55 years.
Generally healthy as determined by medical history, physical examination, and screening assessments.
Body Mass Index (BMI) between 18.5 and 29.9 kg/m².
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
NVTIA® Ergothioneine; Placebo
Registered summary
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of NVTIA® Ergothioneine, a branded ergothioneine ingredient, on healthy aging biomarkers and skin health in healthy adults aged 40 to 65 years. Participants will receive either NVTIA® Ergothioneine or a matching placebo once daily for 12 weeks. The primary objective of this study is to evaluate the effects of NVTIA® Ergothioneine supplementation on biomarkers associated with oxidative stress and healthy aging. The full summary is on the listing.
Where, as registered
No US site; Bangladesh (1).
RecruitingNCT07451496
PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)
No phase
National University of Singapore
About 20 people
Started Sep 29, 2025
In plain words A study of ergothioneine in people 50 to 80, run by National University of Singapore. It plans to enroll about 20 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 80; healthy volunteers accepted. Conditions: Ageing.
Age 50-80 years (both male and female)
Relatively healthy and in stable health condition
Not engaged in regular resistance or aerobic training in the past 12 months (i.e., untrained)
VO₂peak below the 75th percentile for age- and sex-specific norms
6 more inclusion criteria and the exclusion criteria are on the listing.
As the population ages, the growing prevalence of age-related diseases is creating substantial challenges for healthcare systems worldwide. Current therapeutic strategies often target individual diseases and decrease mortality without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process itself could prevent, delay, or manage the severity of multiple age-related diseases concurrently, thereby improving overall healthspan and reducing healthcare burdens. The full summary is on the listing.